Research Papers

This database includes peer-reviewed publications authored or funded by TB Alliance. Use the tags on the right to filter by subject, or search for a particular author or term using the search bar.

Displaying 178 papers

In Vitro and In Vivo Activities of the Nitroimidazole TBA-354 against Mycobacterium tuberculosis

10/2014 - Upton AM, Cho S, Yang TJ, et. al. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015 Jan;59(1):136-44. doi: 10.1128/AAC.03823-14.

Tags: Drug Discovery, Pharmacokinetics, Preclinical Data, TBA-354

Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 withconcomitant lopinavir-ritonavir, efavirenz, or rifampin

9/2014 - Dooley KE, Luetkemeyer AF, Park JG, et. al. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother. 2014 Sep;58(9):5245-52.

Tags: Clinical Development, Clinical Trial Results, Pharmacokinetics, Pretomanid/PA-824, TB-HIV

Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility

8/2014 - Streicher EM, Maharaj K, York T, et. al. Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility.J Clin Microbiol. 2014 Nov;52(11):4056-7. doi: 10.1128/JCM.02438-14

Tags: Drug-Sensitivity Testing, MDR-TB, Pyrazinamide

Burden of childhood tuberculosis in 22 high-burden countries, a mathematical modelling study

7/2014 - Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. Lancet Glob Health. 2014 Aug;2(8):e453-9. doi: 10.1016/S2214-109X(14)70245-1.

Tags: Childhood TB, TB Burden, TB Market

Tuberculosis drug discovery and emerging targets

6/2014 - Mdluli K, Kaneko T, Upton A. Tuberculosis drug discovery and emerging targets. Ann N Y Acad Sci. 2014 Sep;1323:56-75. doi: 10.1111/nyas.12459.

Tags: Advocacy, Drug Discovery, Drug Targets, Editorials, Preclinical Models

Lead optimization of 1,4-azaindoles as antimycobacterial agents

6/2014 - Shirude PS, Shandil RK, Manjunatha MR, et. al. Lead optimization of 1,4-azaindoles as antimycobacterial agents. J Med Chem. 2014 Jul 10;57(13):5728-37. doi: 10.1021/jm500571f.

Tags: Drug Discovery, Pharmacokinetics

1,4-Azaindole, a Potential Drug Candidate for Treatment of Tuberculosis

6/2014 - Chatterji M, Shandil R, Manjunatha MR, et. al. 1,4-azaindole, a potential drug candidate for treatment of tuberculosis.Antimicrob Agents Chemother. 2014 Sep;58(9):5325-31. doi: 10.1128/AAC.03233-14.

Tags: Bedaquiline (TMC-207), Drug Discovery, MDR-TB, Pharmacokinetics, Preclinical Data, Pretomanid/PA-824

Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents

4/2014 - Zhang D, Liu Y, Zhang C, et. al. Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents. Molecules. 2014 Apr 9;19(4):4380-94. doi: 10.3390/molecules19044380.

Tags: Clofazamine, Pharmacodynamics, Pharmacokinetics

Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

4/2014 - Gillespie SH, Crook AM, McHugh TD, et. al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1577-87. doi: 10.1056/NEJMoa1407426.

Tags: Clinical Development, Clinical Trial Results, HRZE, Moxifloxacin, ReMoxTB

Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study.

12/2013 - Lancet Respiratory Medicine

Author(s): Bryant J, Harris S, Parkhill J, Dawson R, Diacon A, van Helden P, Pym A, Mahayiddin A, Chuchottaworn C, Sanne I, Louw C, Boeree M, Hoelscher M, McHugh T, Bateson A, Hunt R, Mwaigwisya S, Wright L, Gillespie S, Bentley, S.

Tags: M.tb. Biology, ReMoxTB

Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects

11/2013 - Winter H, Ginsberg A, Egizi E, et. al. Effect of a High-Calorie, High-Fat Meal on the Bioavailability and Pharmacokinetics of PA-824 in Healthy Adult Subjects. Antimicrob Agents Chemother. 2013 Nov; 57(11): 5516–5520. doi: 10.1128/AAC.00798-13

Tags: Clinical Development, Clinical Trial Results, Pharmacodynamics, Pretomanid/PA-824

Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents

10/2013 - Cooper CB. Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents. J Med Chem. 2013 Oct 24;56(20):7755-60. doi: 10.1021/jm400381v.

Tags: Drug Discovery, Global Pipeline, Preclinical Models

Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen

8/2013 - Dutta NK, Alsultan A, Gniadek TJ, et. al. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother. 2013 Aug;57(8):3910-6. doi: 10.1128/AAC.00761-13.

Tags: HRZE, Moxifloxacin, PaMZ, Preclinical Data, Pretomanid/PA-824, Pyrazinamide

The role of product development partnerships in advancing the development of drugs for unmet needs

6/2013 - Breitstein J, Spigelman M. The role of product development partnerships in advancing the development of drugs for unmet needs. Clin Pharmacol Ther. 2013 Jun;93(6):468-70. doi: 10.1038/clpt.2013.53.

Tags: Advocacy, Editorials, Global Pipeline

Requirements for the clinical evaluation of new anti-tuberculosis agents in children

6/2013 - Donald PR, Ahmed A, Burman WJ, et. al. Requirements for the clinical evaluation of new anti-tuberculosis agents in children. Int J Tuberc Lung Dis. 2013 Jun;17(6):794-9. doi: 10.5588/ijtld.12.0567.

Tags: Advocacy, Childhood TB, Clinical Development, Editorials, Trial Design

Engaging communities in tuberculosis research

6/2013 - Boulanger RF, Seidel S, Lessem E, et. al. Engaging communities in tuberculosis research. Lancet Infect Dis. 2013 Jun;13(6):540-5. doi: 10.1016/S1473-3099(13)70042-2.

Tags: Advocacy, Community Engagement, Editorials

Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients withsputum microscopy smear-positive pulmonary tuberculosis

5/2013 - Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et. al. Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary Tuberculosis. Antimicrob Agents Chemother.

Tags: Bedaquiline (TMC-207), Clinical Development, Clinical Trial Results, Pharmacokinetics

Identification of a small molecule with activity against drug-resistant and persistent tuberculosis

5/2013 - Wang F, Sambandan D, Halder R, et. al. Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):E2510-7. doi: 10.1073/pnas.1309171110.

Tags: Drug Discovery, Drug Targets, MDR-TB, Preclinical Models

Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects

4/2013 - Winter H, Egizi E, Erondu N, et. al. Evaluation of Pharmacokinetic Interaction between PA-824 and Midazolam in Healthy Adult Subjects. Antimicrob Agents Chemother. 2013 Aug; 57(8): 3699–3703.doi: 10.1128/AAC.02632-12

Tags: Clinical Development, Clinical Trial Results, Pretomanid/PA-824

Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents

3/2013 - Hwang JM, Oh T, Kaneko T., et. al. Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents. J Nat Prod. 2013 Mar 22;76(3):354-67. doi: 10.1021/np3007167.

Tags: Drug Discovery, Pharmacodynamics, Pharmacokinetics, Preclinical Data

Pages